中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 10
Oct.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(10): 2174-2179

Pharmacological action of astragaloside Ⅳ in the prevention and treatment of liver diseases and its mechanism

DOI: 10.12449/JCH251032
  • 1.

    Department of Pharmacy，The Fifth People’s Hospital of Chengdu，Chengdu 611130，China

  • 2.

    School of Pharmacy，Chengdu University of Traditional Chinese Medicine，Chengdu 611137，China

Research funding:

National Natural Science Foundation of China (82003828);

Commission-University Joint Innovation Foundation (WXLH202402028);

Sichuan Provincial Administration of Traditional Chinese Medicine Fund (2022CP7147)

More Information
  • Corresponding author: PU Shiyun， pushiyun@cdutcm.edu.cn （ORCID： 0000-0002-0907-6664）
  • Received Date: 2025-03-17
  • Accepted Date: 2025-04-08
  • Published Date: 2025-10-25
    Abstract
  • Astragaloside Ⅳ （AS-Ⅳ） is a natural triterpenoid saponin compound derived from Astragalus membranaceus and has shown significant potential in the regulation of liver diseases. This article reviews the latest research advances in AS-Ⅳ in the field of liver diseases in China and globally， and it is found that AS-Ⅳ exerts a liver-protecting effect by regulating lipid metabolism， exerting an anti-tumor/anti-inflammatory/anti-fibrotic effect， and modulating gut microbiota. Its mechanism of action involves multiple signaling pathways， such as AMPK， NLRP3， NF-κB， JAK2/STAT3， and Nrf2. These research findings provide a scientific basis for the development of liver-protecting drugs or functional foods based on the natural product AS-Ⅳ.

     

    • FullText(HTML)
  • loading
    • References(50)
  • [1]
    WANG FS, FAN JG, ZHANG Z, et al. The global burden of liver disease: The major impact of China[J]. Hepatology, 2014, 60( 6): 2099- 2108. DOI: 10.1002/hep.27406.
    [2]
    DEVARBHAVI H, ASRANI SK, ARAB JP, et al. Global burden of liver disease: 2023 update[J]. J Hepatol, 2023, 79( 2): 516- 537. DOI: 10.1016/j.jhep.2023.03.017.
    [3]
    SHI H, ZHOU P, GAO G, et al. Astragaloside IV prevents acute myocardial infarction by inhibiting the TLR4/MyD88/NF-κB signaling pathway[J]. J Food Biochem, 2021, 45( 7): e13757. DOI: 10.1111/jfbc.13757.
    [4]
    SHEN Q, FANG J, GUO H, et al. Astragaloside IV attenuates podocyte apoptosis through ameliorating mitochondrial dysfunction by up-regulated Nrf2-ARE/TFAM signaling in diabetic kidney disease[J]. Free Radic Biol Med, 2023, 203: 45- 57. DOI: 10.1016/j.freeradbiomed.2023.03.022.
    [5]
    GUO JN, LE YF, YUAN AN, et al. Astragaloside IV ameliorates cisplatin-induced liver injury by modulating ferroptosis-dependent pathways[J]. J Ethnopharmacol, 2024, 328: 118080. DOI: 10.1016/j.jep.2024.118080.
    [6]
    LIU X, DING YP, JIANG CX, et al. Astragaloside IV ameliorates radiation-induced nerve cell damage by activating the BDNF/TrkB signaling pathway[J]. Phytother Res, 2023, 37( 9): 4102- 4116. DOI: 10.1002/ptr.7872.
    [7]
    WANG JY, PU XY, ZHUANG HW, et al. Astragaloside IV alleviates septic myocardial injury through DUSP1-Prohibitin 2 mediated mitochondrial quality control and ER-autophagy[J]. J Adv Res, 2025, 75: 561- 580. DOI: 10.1016/j.jare.2024.10.030.
    [8]
    KIM J, YANG G, KIM Y, et al. AMPK activators: Mechanisms of action and physiological activities[J]. Exp Mol Med, 2016, 48( 4): e224. DOI: 10.1038/emm.2016.16.
    [9]
    ZHOU M, LIU X, WU YJ, et al. Mechanism of astragaloside Ⅳ on db/db mice with type 2 diabetes mellitus and non-alcoholic fatty liver disease based on AMPK signaling pathway[J]. Chin J Exp Tradit Med Form, 2024, 30( 5): 72- 79. DOI: 10.13422/j.cnki.syfjx.20232039.

    周敏, 刘秀, 吴勇军, 等. 基于AMPK信号通路探讨黄芪甲苷对db/db小鼠2型糖尿病合并非酒精性脂肪肝病的作用机制[J]. 中国实验方剂学杂志, 2024, 30( 5): 72- 79. DOI: 10.13422/j.cnki.syfjx.20232039.
    [10]
    ZHOU B, ZHOU DL, WEI XH, et al. Astragaloside IV attenuates free fatty acid-induced ER stress and lipid accumulation in hepatocytes via AMPK activation[J]. Acta Pharmacol Sin, 2017, 38( 7): 998- 1008. DOI: 10.1038/aps.2016.175.
    [11]
    AJOOLABADY A, KAPLOWITZ N, LEBEAUPIN C, et al. Endoplasmic reticulum stress in liver diseases[J]. Hepatology, 2023, 77( 2): 619- 639. DOI: 10.1002/hep.32562.
    [12]
    WANG M, KAUFMAN RJ. Protein misfolding in the endoplasmic reticulum as a conduit to human disease[J]. Nature, 2016, 529( 7586): 326- 335. DOI: 10.1038/nature17041.
    [13]
    LEBEAUPIN C, VALLÉE D, HAZARI Y, et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease[J]. J Hepatol, 2018, 69( 4): 927- 947. DOI: 10.1016/j.jhep.2018.06.008.
    [14]
    LEE JH, LEE J. Endoplasmic reticulum(ER) stress and its role in pancreatic β-cell dysfunction and senescence in type 2 diabetes[J]. Int J Mol Sci, 2022, 23( 9): 4843. DOI: 10.3390/ijms23094843.
    [15]
    JALAL IA, ELKHOELY A, MOHAMED SK, et al. Linagliptin and secoisolariciresinol diglucoside attenuate hyperlipidemia and cardiac hypertrophy induced by a high-methionine diet in rats via suppression of hyperhomocysteinemia-induced endoplasmic reticulum stress[J]. Front Pharmacol, 2023, 14: 1275730. DOI: 10.3389/fphar.2023.1275730.
    [16]
    GLICK D, BARTH S, MACLEOD KF. Autophagy: Cellular and molecular mechanisms[J]. J Pathol, 2010, 221( 1): 3- 12. DOI: 10.1002/path.2697.
    [17]
    XIAO ZL, LU CX, ZHOU DN, et al. Role of lipophagy in the prevention and treatment of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2024, 40( 7): 1450- 1458. DOI: 10.12449/JCH240725.

    肖智利, 卢晨霞, 周丹妮, 等. 脂肪自噬在非酒精性脂肪性肝病防治中的作用[J]. 临床肝胆病杂志, 2024, 40( 7): 1450- 1458. DOI: 10.12449/JCH240725.
    [18]
    SINHA RA. Autophagy: A cellular guardian against hepatic lipotoxicity[J]. Genes(Basel), 2023, 14( 3): 553. DOI: 10.3390/genes14030553.
    [19]
    ZHU YF, SU Y, ZHANG J, et al. Astragaloside IV alleviates liver injury in type 2 diabetes due to promotion of AMPK/mTOR-mediated autophagy[J]. Mol Med Rep, 2021, 23( 6): 437. DOI: 10.3892/mmr.2021.12076.
    [20]
    LIU G, WANG YH, ZHANG T, et al. Astragaloside-IV promotes autophagy via the Akt/mTOR pathway to improve cellular lipid deposition[J]. Medicine(Baltimore), 2024, 103( 16): e37846. DOI: 10.1097/MD.0000000000037846.
    [21]
    MANSOURI A, GATTOLLIAT CH, ASSELAH T. Mitochondrial dysfunction and signaling in chronic liver diseases[J]. Gastroenterology, 2018, 155( 3): 629- 647. DOI: 10.1053/j.gastro.2018.06.083.
    [22]
    LUO ZX, WANG YQ, XUE MZ, et al. Astragaloside IV ameliorates fat metabolism in the liver of ageing mice through targeting mitochondrial activity[J]. J Cell Mol Med, 2021, 25( 18): 8863- 8876. DOI: 10.1111/jcmm.16847.
    [23]
    VALENTA T, HAUSMANN G, BASLER K. The many faces and functions of β-catenin[J]. EMBO J, 2012, 31( 12): 2714- 2736. DOI: 10.1038/emboj.2012.150.
    [24]
    HE T, WANG FF, LIU ZQ, et al. Astragaloside affects HepG-2 cell proliferation and apoptosis through Wnt/β-catenin pathway[J]. World Chin Med, 2020, 15( 24): 3787- 3791. DOI: 10.3969/j.issn.1673-7202.2020.24.011.

    何婷, 王斐斐, 柳仲秋, 等. 黄芪甲苷通过Wnt/β-catenin途径影响HepG-2细胞的增殖和凋亡[J]. 世界中医药, 2020, 15( 24): 3787- 3791. DOI: 10.3969/j.issn.1673-7202.2020.24.011.
    [25]
    QIN CD, MA DN, REN ZG, et al. Astragaloside IV inhibits metastasis in hepatoma cells through the suppression of epithelial-mesenchymal transition via the Akt/GSK-3β/β-catenin pathway[J]. Oncol Rep, 2017, 37( 3): 1725- 1735. DOI: 10.3892/or.2017.5389.
    [26]
    FOLKMAN J. Angiogenesis[J]. Annu Rev Med, 2006, 57: 1- 18. DOI: 10.1146/annurev.med.57.121304.131306.
    [27]
    ZHANG S, TANG DC, ZANG WH, et al. Synergistic inhibitory effect of traditional Chinese medicine astragaloside IV and curcumin on tumor growth and angiogenesis in an orthotopic nude-mouse model of human hepatocellular carcinoma[J]. Anticancer Res, 2017, 37( 2): 465- 473. DOI: 10.21873/anticanres.11338.
    [28]
    OGIHARA T, MIZOI K, KAMIOKA H, et al. Physiological roles of ERM proteins and transcriptional regulators in supporting membrane expression of efflux transporters as factors of drug resistance in cancer[J]. Cancers(Basel), 2020, 12( 11): 3352. DOI: 10.3390/cancers12113352.
    [29]
    LESLIE EM, DEELEY RG, COLE SPC. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP(ABCG2) in tissue defense[J]. Toxicol Appl Pharmacol, 2005, 204( 3): 216- 237. DOI: 10.1016/j.taap.2004.10.012.
    [30]
    QU XY, GAO H, ZHAI JH, et al. Astragaloside IV enhances cisplatin chemosensitivity in hepatocellular carcinoma by suppressing MRP2[J]. Eur J Pharm Sci, 2020, 148: 105325. DOI: 10.1016/j.ejps.2020.105325.
    [31]
    FU YJ, MACKOWIAK B, FENG DC, et al. MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression[J]. Gut, 2023, 72( 10): 1942- 1958. DOI: 10.1136/gutjnl-2022-327924.
    [32]
    YUAN ML, ZHANG XS, YUE FX, et al. CircNOLC1 promotes colorectal cancer liver metastasis by interacting with AZGP1 and sponging miR-212-5p to regulate reprogramming of the oxidative pentose phosphate pathway[J]. Adv Sci(Weinh), 2023, 10( 33): e2205229. DOI: 10.1002/advs.202205229.
    [33]
    DINAMI R, POMPILI L, PETTI E, et al. MiR-182-3p targets TRF2 and impairs tumor growth of triple-negative breast cancer[J]. EMBO Mol Med, 2023, 15( 1): e16033. DOI: 10.15252/emmm.202216033.
    [34]
    MA Y, LI Y, WU TT, et al. Astragaloside IV attenuates programmed death-ligand 1-mediated immunosuppression during liver cancer development via the miR-135b-5p/CNDP1 axis[J]. Cancers(Basel), 2023, 15( 20): 5048. DOI: 10.3390/cancers15205048.
    [35]
    MIN YQ, LI S, LIU XH, et al. Research advances in the cascade interaction between reactive oxygen species/reactive nitrogen species and the NF-κB signaling pathway in liver fibrosis[J]. J Clin Hepatol, 2023, 39( 6): 1454- 1460. DOI: 10.3969/j.issn.1001-5256.2023.06.031.

    闵远骞, 李姗, 刘湘花, 等. 活性氧/活性氮与NF-κB信号通路级联交互在肝纤维化中的作用[J]. 临床肝胆病杂志, 2023, 39( 6): 1454- 1460. DOI: 10.3969/j.issn.1001-5256.2023.06.031.
    [36]
    CHENG MX, CHEN ZZ, CAI YL, et al. Astragaloside IV protects against ischemia reperfusion in a murine model of orthotopic liver transplantation[J]. Transplant Proc, 2011, 43( 5): 1456- 1461. DOI: 10.1016/j.transproceed.2011.02.066.
    [37]
    LIU YL, ZHANG QZ, WANG YR, et al. Astragaloside IV improves high-fat diet-induced hepatic steatosis in nonalcoholic fatty liver disease rats by regulating inflammatory factors level via TLR4/NF-κB signaling pathway[J]. Front Pharmacol, 2021, 11: 605064. DOI: 10.3389/fphar.2020.605064.
    [38]
    FU JN, WU H. Structural mechanisms of NLRP3 inflammasome assembly and activation[J]. Annu Rev Immunol, 2023, 41: 301- 316. DOI: 10.1146/annurev-immunol-081022-021207.
    [39]
    WU S, WEN F, ZHONG XB, et al. Astragaloside IV ameliorate acute alcohol-induced liver injury in mice via modulating gut microbiota and regulating NLRP3/caspase-1 signaling pathway[J]. Ann Med, 2023, 55( 1): 2216942. DOI: 10.1080/07853890.2023.2216942.
    [40]
    DING YP, DONG XQ, YIFAN MA, et al. Astragaloside IV plays a role in reducing radiation-induced liver inflammation in mice by inhibiting thioredoxin-interacting protein/nod-like receptor protein 3 signaling pathway[J]. J Tradit Chin Med, 2023, 43( 1): 87- 94. DOI: 10.19852/j.cnki.jtcm.2023.01.008.
    [41]
    QU XY, GAO H, TAO LN, et al. Astragaloside IV protects against cisplatin-induced liver and kidney injury via autophagy-mediated inhibition of NLRP3 in rats[J]. J Toxicol Sci, 2019, 44( 3): 167- 175. DOI: 10.2131/jts.44.167.
    [42]
    YAN Y, ZHANG LB, MA R, et al. Jolkinolide B ameliorates rheumatoid arthritis by regulating the JAK2/STAT3 signaling pathway[J]. Phytomedicine, 2024, 124: 155311. DOI: 10.1016/j.phymed.2023.155311.
    [43]
    ZHANG HY, CHANG XR. Astragaloside Ⅳ inhibits JAK2/STAT3 signaling pathway and alleviates severe acute pancreatitis-associated acute liver injury in rats[J]. Chin J Pathophysiol, 2016, 32( 6): 984- 989. DOI: 10.3969/j.issn.1000-4718.2016.06.004.

    张海云, 常香荣. 黄芪甲苷通过抑制JAK2/STAT3信号通路减轻重症急性胰腺炎大鼠肝损伤[J]. 中国病理生理杂志, 2016, 32( 6): 984- 989. DOI: 10.3969/j.issn.1000-4718.2016.06.004.
    [44]
    LI XM, WANG XL, HAN CY, et al. Astragaloside IV suppresses collagen production of activated hepatic stellate cells via oxidative stress-mediated p38 MAPK pathway[J]. Free Radic Biol Med, 2013, 60: 168- 176. DOI: 10.1016/j.freeradbiomed.2013.02.027.
    [45]
    ZHAO XM, ZHANG J, LIANG YN, et al. Astragaloside IV synergizes with ferulic acid to alleviate hepatic fibrosis in bile duct-ligated cirrhotic rats[J]. Dig Dis Sci, 2020, 65( 10): 2925- 2936. DOI: 10.1007/s10620-019-06017-3.
    [46]
    EZHILARASAN D. Hepatic stellate cells in the injured liver: Perspectives beyond hepatic fibrosis[J]. J Cell Physiol, 2022, 237( 1): 436- 449. DOI: 10.1002/jcp.30582.
    [47]
    WANG SG, LI JY, HUANG H, et al. Anti-hepatitis B virus activities of astragaloside IV isolated from Radix Astragali[J]. Biol Pharm Bull, 2009, 32( 1): 132- 135. DOI: 10.1248/bpb.32.132.
    [48]
    ZHAI YY, ZHOU WL, YAN X, et al. Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling[J]. Phytomedicine, 2022, 107: 154444. DOI: 10.1016/j.phymed.2022.154444.
    [49]
    NIU KQ, CHANG H, LYU GF, et al. Inhibitory effect of astragaloside Ⅳ on cisplatin-induced liver injury in mice and its mechanism[J]. J Jilin Univ(Med Ed), 2025, 51( 2): 370- 377. DOI: 10.13481/j.1671-587X.20250211.

    牛凯琦, 昌贺, 律广富, 等. 黄芪甲苷对顺铂所致小鼠肝损伤的抑制作用及其机制[J]. 吉林大学学报(医学版), 2025, 51( 2): 370- 377. DOI: 10.13481/j.1671-587X.20250211.
    [50]
    LI L, HUANG WX, WANG SK, et al. Astragaloside IV attenuates acetaminophen-induced liver injuries in mice by activating the Nrf2 signaling pathway[J]. Molecules, 2018, 23( 8): 2032. DOI: 10.3390/molecules23082032.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (51) PDF downloads(9) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return